Study protocol for a randomized controlled pilot-trial on the semiocclusive treatment of fingertip amputation injuries using a novel finger cap by Schultz, Jurek et al.
Study Protocol Clinical Trial Medicine®
OPENStudy protocol for a randomized controlled pilot-
trial on the semiocclusive treatment of ﬁngertip
amputation injuries using a novel ﬁnger cap
Jurek Schultz, Dr meda,
∗
, Susann Leupold, Dipl hum-biola, Xina Grählert, Dr rer natb,
Roland Pfeiffer, Dr rer natb, Uta Schwanebeckb, Percy Schröttner, Dr medc, Barbara Djawidb,
Wladislav Artsimovichd, Karol Kozak, Prof Drd,e,f, Guido Fitze, Prof Dr medaAbstract
R
in
A
o
w
ﬁ
A
a
D
D
a
p
F
R
T
a
U
U
∗
D
C
T
a
M
R
hIntroduction: Fingertip amputation injuries are common in all ages. Conservatively treated ﬁngertips can regenerate skin and soft
tissues to form a functionally and cosmetically excellent new ﬁngertip. Little is known about this ability that, in humans, is conﬁned to
the ﬁngertips. Even less is known about the role of the bacteria that regularly colonize these wounds without negative impact on
regeneration and healing.
As an alternative to surgery, self-adhesive ﬁlm dressings are commonly used to establish a wet chamber around the injury. These
dressings leakmalodorous wound ﬂuid eventually until the wound is dry. Having that into consideration, we have therefore developed
a silicone ﬁnger cap that forms a mechanically protected, wet chamber around the injury for optimal regeneration conditions. It
contains a puncturable reservoir for excess wound ﬂuid, which can be thus routinely analyzed for diagnostic and research purposes.
This study protocol explains the ﬁrst randomized controlled trial (RCT) on the semiocclusive treatment of ﬁngertip amputations in
both children and adults comparing traditional ﬁlm dressings with the novel silicone ﬁnger cap. Being the ﬁrst RCT using 2 medical
devices not yet certiﬁed for this indication, it will gather valuable information for the understanding of ﬁngertip regeneration and the
design of future deﬁnitive studies.
Methodsandanalysis:By employing an innovative pseudo-cross-over-design with a dichotomous primary endpoint based on
patients preference, this pilot study will gain statistically signiﬁcant data with a very limited sample size. Our RCT will investigate
acceptance, safety, effectiveness, and efﬁcacy of this novel medical device while gathering information on the clinical course and
outcome of conservatively treated ﬁngertip injuries. A total of 22 patients older than 2 years will be randomly assigned to start the
conservative treatment with either the traditional ﬁlm-dressing or the novel ﬁnger cap. The treatment will be changed to the other
alternative for another 2 weeks before the patient or the guardian is confronted with the decision of which method they would prefer
for the rest of the treatment (if required).andomization, monitoring, evaluation of study data, statistics, and sponsor ofﬁce are committed to the Coordinating Centre for Clinical Trials Dresden, an institute
dependent of the Department of Pediatric Surgery.
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Fingertip injuries are very common. In pediatric emergency
departments, ﬁngertip injuries account for up to 2%[1] of
appearances of children under 14 years of age with 25% of these
injuries beingmore serious, needing surgical treatment, in 15%of
the cases under general anesthetics.[1]
Already in 1974, Illingworth reported on pediatric ﬁngertip
injuries with substance loss, that were treated conservatively with
very good success.[2] The superiority of the conservative
approach was afterwards demonstrated in comparative stud-
ies.[2–5] Later, sulphadiazine gloves, and thus a method of
occlusive dressing that formed a wet chamber around the injury,
were used.[6] Söderberg et al[7] used ink tattoos on the wound
edge to show that human ﬁngertips regenerate de novo under
conservative treatment. Additionally, the use of ﬁlm dressings to
occlude the injured ﬁngertips was demonstrated in a series of 200
patients in 1993.[8] The authors concluded that this kind of
treatment should be recommended for all ﬁngertip injuries.[8]
Surgical approaches for ﬁngertip amputation injuries that
cannot be subjected to primary closure include stump plasties,
local, or distant ﬂaps (eg, V-Y-plasty, etc), microsurgical
replantation, composite grafts, or skin transplants.[9] There are
only little and conﬂicting data on the indication of conservative
versus surgical techniques. Controversies also exist on necessary
wound disinfection, if exposed bone should be shortened before
any occlusive dressing is applied and, whether or not, amputates
should be reattached as composite grafts.[10–12]
In many centers the conservative management of ﬁngertip
injuries is accomplished with self-adhesive ﬁlm dressings.[8,13]
However, this management is sometimes difﬁcult, especially since
these dressings do not stick to wet skin. Conventional dressings
do not form a protected chamber around the wound, additional
splinting is often needed[5,6] and leakage of malodorous wound
ﬂuid is very disturbing. Therefore, we have optimized the
conventional occlusive dressings by applying techniques known
from silicone ﬁnger ortheses and designed a novel silicone ﬁnger
cap that deals with the aforementioned issues.
This novel silicone ﬁnger cap is now evaluated for the ﬁrst time
in an investigator initiated, randomized controlled clinical trial
regarding the acceptance of the ﬁnger cap in comparison to
conventional ﬁlm dressings using a pseudo-cross-over study
design. As both medical devices are not certiﬁed for the treatment
of deeper wounds and exposed bone, this randomized controlled
trial (RCT) is a pilot study by deﬁnition. By employing a pseudo-
cross-over-design with a summative dichotomous primary end-
point (patient preference) wewill gain statistically signiﬁcant data
despite the limited sample size while gathering important data
with a variety of secondary end-points to plan for future deﬁnitive
studies and better understand ﬁngertip regeneration.
As well as evaluating the safety and efﬁcacy of this novel
treatment, secondary endpoints of our study include clinical,
functional, microbiological, and quality-of-life parameters.2Additionally, our RCT includes a substudy for the harvesting
of wound ﬂuids from the puncturable reservoir incorporated in
our ﬁnger cap. This will allow the search for human and bacterial
soluble factors that may promote tissue regeneration and limit
bacterial growth to local colonization. Our study starts enrolling
patients in August 2017.2. Methods and analysis
2.1. Study design
This pilot study is a monocentric, prospective, randomized,
controlled clinical trial. Primarily, it will investigate the
acceptance of the silicone ﬁnger cap in comparison to
conventional ﬁlm dressings. Using sealed neutral envelopes
prepared by external staff from the Coordinating Centre for
Clinical Trials, our patients will be randomly assigned by the
study doctors to begin their treatment either with the ﬁnger cap or
the ﬁlm dressing. After 2 weeks they will be changed to the other
treatment modality. After another 2 weeks have passed, patients/
guardians will have to decide prior to the dressing change which
treatment they would like to receive thereafter if further occlusion
is needed. The primary clinical endpoint of this pseudo-cross-over
study (Fig. 1) is the rate of patients/guardians who decide to
continue their treatment with the silicone ﬁnger cap. Further
secondary endpoints include the determination of the safety of
the ﬁnger cap in comparison to the ﬁlm dressing and the
determination of disease-speciﬁc quality of life during the
treatment with the silicone ﬁnger cap in comparison to the ﬁlm
dressing using a modiﬁed quality of life WuerzburgWound Score
regarding pain during application and treatment with the ﬁnger
cap, restrictions in daily activities and quality of life.[14] Also the
necessity of unplanned dressing changes in comparison to the ﬁlm
dressing and changes in microbiological colonization in the
wound during the treatment will be registered. Additionally, we
will measure the reepithelialization rate and determine the tissue
growth at 28 days and at 4 months after the injury. We will also
test the function of the regenerated perspiratory glands and the
clinical outcome in terms of sensitivity and motility of the injured
ﬁngertip as well as cosmetic aspects.
2.2. Treatment group
The silicone ﬁnger cap consists of a thin and soft silicone shaft
that surrounds the basis of the ﬁnger and provides the
semiocclusive seal without the need for additional adhesives. It
is thus a further development of conventional occlusive means
such as self-adhesive ﬁlms or ﬁngers of sterile rubber gloves. The
ﬁnger cap forms a protected chamber of more rigid silicone
around the distal phalanx that is close to the original, anatomical
form, and size of the ﬁngertip. The more rigid silicone is
continued in a narrow bar all the way to the base of the ﬁnger cap
thus splinting the injured ﬁnger enough to care for undisturbed
Figure 1. Pseudo-cross-over study design of this study.
Schultz et al. Medicine (2017) 96:41 www.md-journal.comhealing while allowing some movement in all ﬁnger joints. A
reservoir for excess wound ﬂuid is connected to the wound
chamber by capillaries, thus enabling free diffusion in between
the wound and the reservoir (Fig. 2). This reservoir can be
punctured with a regular injection needle. The used medical
silicone Dragon Skin Series Part A&B (KauPo, Spaichingen,
Germany), Silastic Q7-4720 Biomedical Grade ETR Elastomer
and Silastic Q7-4765 Biomedical Grade ETR Elastomer (Dow
Corning, Midland, TX) is permeable to oxygen to some extent
but impermeable to water vapor. For this series all ﬁnger caps are
individually handcrafted by Orthopedic and Rehabilitation
Engineering Dresden (GmbH), Dresden, Germany, the sponsor
of this clinical trial. Besides, the sponsor ofﬁce was committed to
the Coordinating Centre for Clinical Trials Dresden.
2.3. Control group
In our control group, we start the treatment with a self-adhesive
polyurethane ﬁlm dressing as it is used inmost centers as standard
therapy.[4,8,13,15–18] Opsite Flexigrid transparent dressing (Smith
&NephewMedical Limited, Hull, England) is a transparent ﬁlm
dressing, comprised of a polyurethane ﬁlm with acrylic adhesive.
It is Communauté Européenne (certiﬁcation mark indicating
conformity with European legislation)-certiﬁed and it is classiﬁed
according to the European classiﬁcation of medical devices in
group IIa.Figure 2. Novel silicone ﬁnger cap. (A) dorsal view, (B) sagittal view: (1) apex,
(2) protective cap of rigid silicone, (3) reservoir, (4) capillary, (5) chamber for
injured ﬁnger, (6) thin and soft silicone, (7) incorporated splint of more rigid
silicone, and (8) base.2.4. Inclusion and exclusion criteria
The participants are recruited by trained surgeons in the
Emergency Department of the University Hospital Carl Gustav
Carus at the Technische Universität Dresden, Germany. We
include male and female patients older than 2 years with full skin3
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unsuitable for primary surgical closure without further substance
loss. No more than 5 ﬁngers per patient may be injured. Patients
must have a circumference of the proximal phalanx in between
3.0 and 9.0cm. In addition, a signed written informed consent
must exist.
We exclude the participation of any patient with known
hypersensitivity against medical silicone or self-adhesive ﬁlms.
Further exclusion criteria are bony injuries requiring a surgical
intervention, bite injuries, or chronic dermatological disorders
of the hand. Furthermore, intake of medications affecting
wound healing, such as systemic (noninhalative) glucocorti-
coids, immunosuppressive, or blood-thinning medications are
exclusion criteria. Patients with a known wound healing
disorder are also excluded from this clinical trial. In addition,
ongoing or recently ﬁnished chemotherapy, immunodeﬁcien-
cies or diabetes mellitus, are exclusion criteria. In accordance
to x20 of the German Medical Device Act, pregnant or
breastfeeding women, as well as any women, when a
pregnancy at the beginning or during the course of the study
cannot be ruled out (ie, not postmenopausal, no bi-lateral
oophorectomy or hysterectomy, no contraceptive method with
pearl index less than 1%, no sexual abstinence, or partner
with vasectomy) will have to be excluded. Beyond that,
patients who are suffering from an addiction or other diseases,
which do not allow them to assess the entity, scope, and
possible consequences of this clinical trial are also excluded.
The same applies for patients who are not cooperative or
who already participated in other clinical trials within the last
4 weeks.2.5. Procedure
Screening, recruitment, and treatment of our patients take place
in our emergency department. Initially, the patient’s medical
history along with the accident history is obtained. All patients
with ﬁngertip amputations who present themselves to the
emergency department are informed about this clinical trial. The
injury is examined and the inclusion respectively exclusion
criteria are checked. We routinely perform an X-ray examina-
tion to exclude bony injuries. Additionally women of childbear-
ing age have to provide a pregnancy test prior to that. In case all
inclusion and no exclusion criteria are fulﬁlled patients get
comprehensively informed about the clinical trial and the
informed consent is obtained by the trained surgeon. Randomi-
zation takes place through prepared nontransparent and
consecutively numbered envelops and determines the initial
treatment group (conventional ﬁlm dressing or silicone ﬁnger
cap). Afterwards, the respective occlusive dressing is applied
according to the randomization result. We check the dressing 1
day after initial application for correct ﬁtting. Afterwards we
conduct clinical controls weekly to check for correct ﬁtting of the
occlusive dressing, to enquire possible adverse events and
serious adverse events, and to take photos of the dressing and
possibly of the wound. In case, the patient has got a silicone
ﬁnger cap we aspirate wound ﬂuid out of the reservoir to
examine the microbiological colonization of the wound. If the
patient has got an occlusive ﬁlm dressing, no microbiological
examination can be performed except for an initial smear and a
2nd smear when the ﬁlm dressing is removed after 2 weeks. As a
substudy of this clinical trial, excess wound ﬂuid that is not used
for microbiological analyses is preserved at 80 °C for future
proteome analyses. Furthermore, patients are asked to complete4a modiﬁed quality of life Wuerzburg Wound Score at each of
their visits.
On day 14 after the injury, the occlusive dressing method is
changed. Patients treated with the conventional ﬁlm dressing get
a silicone ﬁnger cap and vice versa. Further 14 days later the
patient decides which dressing she or he respectively the
guardians would prefer for the remaining treatment if needed
before the dressing is removed. The chosen treatment is then
applied if further treatment is needed. At day 42 after the injury
the treatment of the wound is orderly ﬁnished and the wound
should be reepithelialized. The occlusive dressing is removed and
photographs of the injury site are taken. If the wound is not fully
epithelialized at this point, a conventional ﬁlm dressing is used as
long as further occlusion is needed. Final follow-up examination
takes place 4 months after the injury. At the follow-up we test the
function of the perspiratory glands and the regeneration of the
ﬁngerprint using Moberg Ninhydrin test.[19] Also the range of
motion in the distal interphalangeal, proximal interphalangeal
and metacarpophalangeal joints, and the 2-point-discrimination
threshold in the area of the injury is checked in comparison to the
corresponding ﬁnger of the contralateral hand.[20] Moreover, we
also measure the soft tissue thickness above the bone in the region
of the healed injury using medical ultrasound. Finally, patients
have to complete a follow-up questionnaire. At each visit the
dressing or, when applicable, the exposed ﬁnger is photographed
from all perspectives. High deﬁnition photographs will be
digitally analyzed and kept for documentation purposes. In this
study, we will introduce a new volume-rendering method for
monitoring ﬁnger growth 3-dimensionally. Photographs will be
rendered in 3-dimensional models and advanced 3-dimensional
segmentation, and ﬁltering algorithms will be used to measure
volume progress of the injured ﬁnger. This method will allow
monitoring of tissue recovery in micrometers quality.
2.6. Statistics
2.6.1. Proposed sample size. There is no certiﬁed medical
device available for the conservative management of ﬁngertip
amputation injuries. Opsite Flexigrid (Smith & NephewMedical
Limited, Hull, England) has not been certiﬁed for full thickness
amputations injuries as described, and our novel ﬁnger cap has
never been used before in a controlled trial. Therefore, this study
is per deﬁnition a pilot study that has to be limited to a small
sample size in order to comply to German and European
legislation as well as to guidelines of good clinical practice.
The primary objective is the rate of patients who decide for
the silicone ﬁnger cap at day 28. At this point they have
experienced both methods (conventional ﬁlm dressings and
silicone ﬁnger cap) for 2 weeks each. This rate can be regarded
as a measure of the acceptance of the silicone ﬁnger cap. If 80%
of the patients in this study decide for the silicone ﬁnger cap we
consider the hypothesized superiority of the ﬁnger cap as
veriﬁed. Assuming that approximately 80% of the patients
decide for the silicone ﬁnger cap, 20 patients (95% conﬁdence
interval, one-sided, 65% lower limit, the distance from the rate
to the lower limit of the conﬁdence interval is at most 15%) are
needed (Program nQuery-Advisor 6.01, Copyright© 1995–
2005, Janet D Elashoff). When considering 2 possible drop-
outs, 22 patients must be included.2.7. Randomization
Based on a computer-generated randomization list (nQuery
Advisor 6.01, Janet D. Elashoff), opaque, numbered envelops are
Schultz et al. Medicine (2017) 96:41 www.md-journal.comproduced at the Coordinating Centre for Clinical Trials. These
envelopes contain the randomization result with the assignment
to treatment group A or B (see Fig. 1). They are opened in
ascending order after the consent of the patient/guardian has been
obtained. The study doctor must note the patient identiﬁcation
number and the date and time of the randomization and conﬁrm
by his signature.2.8. Statistical analysis
A list of imaginable complications and risks with possible
management plans is part of the study protocol. In case of
changes in the treatment due to complications or patient requests,
patients can be treated accordingly in our clinic. All randomized
patients who will be treated with the silicone ﬁnger cap or the ﬁlm
dressing will be included in the intent-to-treat-analyses.
The primary objective of the study is to verify the hypothesis
that the silicone ﬁnger cap is superior to the conventional ﬁlm
dressing in regards to its acceptance by the patients/guardians.
The primary endpoint is the rate of patients who decide up to day
28 to continue their treatment with the silicone ﬁnger cap. If this
rate is at least 80% and the lower limit of the conﬁdence interval
is not less than 65%, the silicone ﬁnger cap is considered to be
much better accepted than the conventional method.
The secondary target parameters are exploratively evaluated.
Secondary endpoints are analyzed according to their scale level:
for steady endpoints, mean and standard deviation, or medians
and quartiles (graphically corresponding to conﬁdence intervals
or boxplots), for the categorical endpoints absolute and
appropriate relative frequencies are used. Depending on the
distribution of the variables to be analyzed the t test, the U test
and the Chi test[2] are used. For paired comparisons, the paired t
test is used in the case of normally and the Wilcoxon test in the
case of nonnormally distributed variables. Sub-group analyses
according to patient age, injury severity, andmechanism of injury
will be performed if possible. The statistical analysis is carried out
using the SPSS program system (International Business Machines
Corp. New Orchard Road, Armonk, NY) and the SAS System
(SAS Institute Inc., 100 SAS Campus Drive, Cary, NC) for
Windows program in the currently available versions.2.9. Data management
All efforts will be made to avoid missing data, especially for the
main target criteria. If a patient discontinues the trial, but a ﬁnal
visit was done, the data of this visit will be used for calculation of
the main target criteria. The speciﬁc dealing of missing data will
be determined in a data review meeting before starting statistical
analyses.
All relevant patient data and test results have to be documented
as soon as possible in an electronical Case Report Form (eCRF)
and have to match with the source data. Source data will be
veriﬁed by clinical monitoring according to the monitoring
manual. Missing data or deviations will be justiﬁed and corrected
only by authorized persons. Changes and corrections will be
documented with an audit trail of the trial software.
All data that will be excluded before the ﬁrst application of the
investigational product or its reference product also have to be
documented in the eCRF.
Data entry, maintenance, and handling will be done according
to good clinical practice with the trial software MACRO 4
(InferMed Ltd, London, UK). There will be a validation of the
data with programmed validity and consistency checks by the5trial software. After ﬁnishing the investigation, the entry of all
relevant data, and the clariﬁcation of all queries, the data base
will be closed. After these procedures are completed, the data will
be released for statistical analyses.2.10. Monitoring
Because of the low case number a data review committee and
interim analyses are not planned. However, a risk-based
monitoring is performed by the Coordinating Centre for Clinical
Trials Dresden according to DIN EN ISO 14155:2012-01 and
national regulations.
Additionally, every adverse effect or product deﬁciency is part
of the study documentation. Adverse effects have to be
documented in the eCRF. Product deﬁciencies will be reported
directly to the sponsor. Severe adverse events will be reported
according to the regulatory requirements.2.11. Ethics and dissemination
This study was approved by the German Federal Institute for
Drugs and Medical Devices to be conducted in compliance with
x22a Act onMedical Devices (AZ 94.1.05-5660-10348). Besides,
this study was approved by the Ethics Committee of the
Technische Universität Dresden (EK 148042015). Furthermore,
the trial is registered at the European Database on Medical
Devices (EUDAMED-No.: CIV-15-03-013246) and at Clinical-
Trials.gov (NCT03089060; registration date: March 17, 2017).
Participants will be insured with Chubb Insurance Company of
Europe SE for up to €500.000 per participant to cover for any
harms caused by the participation in this trial.
Trial results will be disseminated through scientiﬁc conference
presentations and by publication in scientiﬁc journals. Mod-
iﬁcations of the trial protocol will only be done in consultation
with investigators and the sponsor. Substantial amendments of
the protocol require the approval of the Ethics Committee and the
national authority (German Federal Institute for Drugs and
Medical Devices).Acknowledgments
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